Symbicort Onset of Action 2

The purpose of this study is to compare the early onset of effect of Symbicort compared to Advair Diskus and Ventolin in adults with...

Date First Received: March 26, 2008

Last Updated: March 26, 2008

Verified by: AstraZeneca, March 2008

Clinical Trial Phase: Phase 3 | Start Date: March 2003

Overall Status: Completed

Estimated Enrollment: 48

Brief Summary

Official Title: “A Randomized, Multicenter, Placebo and Active-Controlled, Single-Dose, 4-Period, Crossover Study to Evaluate the Bronchodilating Effect of SYMBICORT pMDI Versus Advair Diskus and Ventolin HFA.”

Condition Keyword(s):

The purpose of this study is to compare the early onset of effect of Symbicort compared to Advair Diskus and Ventolin in adults with asthma

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Crossover Assignment, Efficacy Study

Study Primary Completion Date: August 2003

Intervention(s) in this Clinical Trial

  • Drug: budesonide/formoterol
  • Drug: fluticasone/salmeterol
  • Drug: albuterol

Arms, Groups and Cohorts in this Clinical Trial

  • Experimental: 1
    • budesonide/formoterol
  • Active Comparator: 2
    • fluticasone/salmeterol
  • Active Comparator: 3
    • albuterol

Outcome Measures for this Clinical Trial

Primary Measures

  • FEV1 3 minutes post dose
    • Time Frame: 4 assessments across 4 visits whilst on treatment (visits may be between 3 and 14 days apart)

Secondary Measures

  • 12 hour serial FEV1
    • Time Frame: 4 assessments across 4 visits whilst on treatment (visits may be between 3 and 14 days apart)
  • Patients perception of effect
    • Time Frame: Patients perception of effect

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • At least 18 years of age
  • Diagnosis of asthma and baseline lung function test results as determined by the protocol
  • Required and received inhaled corticosteroids within timeframe and doses specified in the protocol

Exclusion Criteria:

  • Severe asthma or asthma that is markedly effected by seasonal factors
  • Has required and received non-inhaled corticosteroids within the previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Sponsor Information

Lead Sponsor: AstraZeneca

Overall Clinical Trial Officials and Contacts

Catherine Bonuccelli Study Director AstraZeneca  

Additional Information

Information obtained from ClinicalTrials.gov on August 29, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00646009

Study ID Number: SD-039-0733

ClinicalTrials.gov Identifier: NCT00646009

Health Authority: United States: Food and Drug Administration

Clinical Trials Authorship and Review

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.